Table.
Patient Characteristics
| RA-SR | RA-pAF | RA-cAF | LA-SR | LA-pAF | LA-cAF | |
|---|---|---|---|---|---|---|
| Patients, n | 35 | 13 | 17 | 10 | 9 | 15 |
| Sex, m/f | 24/11 | 7/6 | 10/7 | 5/5 | 6/3 | 6/9 |
| Age, y | 67.9±1.5 | 73.9±2.0 | 70.4±1.8 | 53.5±3.6‡ | 65.6±0.9* | 66.3±1.8* |
| Body mass index, kg/m2 | 27.0±0.6 | 27.5±1.3 | 27.0±0.8 | 26.9±1.4 | 26.4±2.0 | 27.7±1.3 |
| CAD, n | 16 | 7 | 2*† | 3 | 1 | 3 |
| MVD/AVD, n | 14 | 2 | 12*† | 4 | 6 | 10 |
| CAD+MVD/AVD, n | 5 | 4 | 3 | 3 | 2 | 2 |
| Hypertension, n | 28 | 10 | 16 | 5‡ | 5 | 11 |
| Diabetes, n | 11 | 6 | 2† | 1 | 1 | 6 |
| Hyperlipidemia, n | 26 | 9 | 12 | 7 | 3 | 13† |
| LVEF, % | 55.8±1.7 | 45.6±3.5* | 53.5±2.5 | 42.0±4.3† | 53.3±2.9 | 43.1±4.5 |
| LAD, mm | 41.3±0.9 | 47.1±1.8 | 48.9±2.2* | 45.6±2.0 | 48.3±2.7 | 50.8±1.6 |
| LVEDD, mm | 50.2±2.5 | 45.2±6.7 | 52.7±2.4 | 59.4±4.1 | 54.8±2.7 | 54.5±2.2 |
| IVS, mm | 11.6±0.3 | 13.9±1.4 | 13.0±0.7 | 10.2±0.6 | 12.9±0.9 | 11.2±0.6 |
| LVPW, mm | 11.2±0.3 | 12.9±0.9 | 12.3±0.6 | 10.2±0.6 | 11.7±0.6 | 11.2±0.4 |
| Digitalis, n | 1 | 3 | 7* | 4‡ | 1 | 8† |
| ACE inhibitors, n | 22 | 6 | 10 | 10‡ | 5* | 9 |
| AT1 blockers, n | 4 | 4 | 3 | 0 | 0 | 3 |
| β-blockers, n | 28 | 9 | 15 | 9 | 6 | 14 |
| Dihydropyridines, n | 6 | 3 | 3 | 1 | 1 | 2 |
| Diuretics, n | 17 | 7 | 14* | 8 | 5 | 10 |
| Nitrates, n | 9 | 5 | 6 | 1 | 7* | 3† |
| Lipid-lowering drugs, n | 22 | 9 | 9 | 7 | 3 | 10 |
CAD indicates coronary artery disease; MVD/AVD, mitral/aortic valve disease; LVEF, left ventricular ejection fraction; LVEDD, left ventricular end-diastolic diameter; LAD, left atrial diameter; IVS, interventricular septum thickness; LVPW, left ventricular posterior wall thickness; ACE, angiotensin-converting enzyme; and AT, angiotensin receptor.
*
P<0.05 versus SR,
†
P<0.05 versus pAF, and
‡
P<0.05 versus corresponding values in RA from ANOVA followed by Bonferroni multiple comparisons procedure for continuous variables and from Fisher exact test for categorical variables.